In Pre-BCR+ ALL cells the BTK inhibitor ibrutinib induced the suppression of some pre-BCR signalling negative regulators, inhibited the phosphorylation of PI3K/Akt network and its substrates, reduced BCL6 levels and synergized with glucocorticoids. This evidence concerns the gene BCR and acute lymphoblastic leukemia.